Pulmonary Arterial Hypertension (PAH) Market
Pulmonary Arterial Hypertension (PAH) Market Study by Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, and Others from 2023 to 2033
Analysis of Pulmonary Arterial Hypertension (PAH) Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Pulmonary Arterial Hypertension (PAH) Market Overview (2023 to 2033)
The global pulmonary arterial hypertension market size was valued at US$ 5.4 Billion in 2023, and is projected to reach US$ 12.7 Billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period from 2023 to 2033.
Pulmonary arterial hypertension is a life-threatening medical disorder characterized by high blood pressure in the arteries that connect the heart and lungs. It causes the artery walls to constrict and thicken, increasing the pressure on the heart to pump blood and weakening the muscles.
Shortness of breath, tiredness, and swelling in the ankles and legs are all symptoms of PAH. Computed tomography (CT) scans, chest X-rays, ventilation-perfusion, and echocardiography studies are all used to diagnose it. Pulmonary arterial hypertension treatment providers are continually focusing on developing novel PAH diagnosis and PAH management solutions to improve patient care and maximize their business potential as well.
One of the primary factors driving the pulmonary arterial hypertension market growth is the rising frequency of cardiovascular diseases and arterial hypertension. Furthermore, the growing senior population, which is more prone to idiopathic pulmonary arterial hypertension (IPAH) and associated pulmonary arterial hypertension (APAH), is fuelling market expansion.
Excessive alcohol consumption, a lack of physical activity, and unhealthy dietary choices have all contributed to an increase in the risk of hypertension and high blood pressure. The aforementioned factors coupled with the development of novel drugs and advanced technologies for PAH treatments such as vasodilators and treprostinil are estimated to favor demand for pulmonary arterial hypertension treatment in the long run.
High demand for generic pulmonary arterial hypertension medications is anticipated to open up new frontiers of opportunities for established as well as new PAH drug providers.
- In April 2023, Dr. Reddy’s Laboratories, a leading pharmaceutical company based in India, announced the launch of its generic treprostinil injection in the United States. The product was made available in 20 mg/20 ml, 50 mg/20 ml, 100mg/20 ml, and 200 mg/20 ml vials for the treatment of pulmonary arterial hypertension.
Other factors, such as increased public awareness of the potential treatment options for heritable pulmonary arterial hypertension and improved healthcare infrastructure around the world, are likely to propel the pulmonary arterial hypertension market.
Contrastingly, the high cost of PAH drugs and therapies coupled with growing awareness regarding the side effects of PAH medications are expected to emerge as major constraints for global market growth in the long run.
| Report Attributes | Details |
|---|---|
|
PAH Market Size (2023) |
US$ 5.4 Billion |
|
Projected Market Value (2033F) |
US$ 12.7 Billion |
|
Global Market Growth Rate (2023 to 2033) |
5.4% CAGR |
|
United States Market Share (2033) |
>35% |
|
Endothelin Receptor Antagonists (ERAs) Segment Share (2023) |
~45% |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is the Prime Focus of New Companies in the Pulmonary Arterial Hypertension Business?
“Capital Raise Essential for New Pulmonary Arterial Hypertension Companies”
Aspiring pulmonary arterial hypertension treatment providers are projected to focus on raising new funding to finance their research and development efforts and improve their business scope on a global scale. Companies are slated to use the raised capital to fund product innovation and take their research programs to the next level.
- In October 2021, ShouTi Pharmaceuticals, a biotech company focusing on developing medicines using advanced computational technology, announced that it had raised US$ 100 million to develop small molecule drugs for different disorders. The company’s most advanced research program at the time was for a PAH drug that was in Phase 1 of development.
- In February 2020, Aria CV, a developer of cardiovascular devices which help treat pulmonary hypertension, announced that it had raised US$ 31 million in a Series B funding round led by Xeraya Capital and other investors. The funds were intended to be used for clinical trials of its lead product in the United States in hopes of commercialization of the same by 2033.
Through this elaborate pulmonary arterial hypertension research by skilled analysts at Fact.MR, a market research and competitive intelligence provider, start-ups can know more about trends such as local supply, pricing trends, product standards, safety regulations, and new developments that could alter the current or future competitive landscape.
What Restraints are Being Faced by PAH Drug Manufacturers?
“Side Effects Associated with PAH Drugs and High Cost of PAH Treatment”
Regulatory bodies around the world have been known to have lengthy drug approval processes to verify the drug's safety and efficacy. These lengthy procedures incur huge costs to drug development companies, which could hamper the overall pulmonary arterial hypertension market development across the study period.
Furthermore, the business of pulmonary arterial hypertension patient care companies is estimated to be restrained by leading companies terminating medications during clinical studies, patients' unawareness of the prevalence of pulmonary arterial hypertension, and high diagnosis and treatment costs.
Country-wise Insights
Why are Pulmonary Arterial Hypertension Drug Suppliers Investing in India?
“Rapidly Rising Prevalence of Diabetes in the Country”
The PAH market in India is expected to grow at the fastest rate over the forecast period due to its huge population, quick economic development, and improved healthcare systems. In addition, rising initiatives for clinical research development are expected to fuel market growth.
Rise in the adoption of unhealthy diets and an increase in life expectancy are two major variables expected to boost diabetes cases in the country and drive the market. The rising prevalence of diabetes, increased generics consumption, the presence of major pharmaceutical companies, and easy access to high-quality pulmonary arterial hypertension treatments are all expected to drive the pulmonary arterial hypertension market.
Why is the United States Seen as an Opportune Market in This Space?
“Prominent Presence of Board-certified Physicians”
The United States is set to be a leading market and account for over 35% share of the global market by 2033.
Pulmonary arterial hypertension causes over 200,000 hospitalizations in the United States each year. The availability of board-certified physicians, rising hospital admissions linked to PAH, and the commercialization of new PAH medications, all of which are accompanied by a promising pharmacological pipeline, are driving market expansion in the United States.
Moreover, the United States PAH market is predicted to accelerate due to the rising prevalence of this illness due to heavy alcohol consumption, quick adoption of a sedentary lifestyle, and rising smoking habits among individuals.
Where in Europe Will Pulmonary Arterial Hypertension Treatment Demand Be High?
“United Kingdom to Lead European Market Expansion”
Surging prevalence of chronic diseases and expanding geriatric population are estimated to be the prime prospects promulgating sales of pulmonary arterial hypertension medications in the United Kingdom over the coming years. Growing pulmonary arterial hypertension awareness and rising availability of advanced PAH patient care solutions in the country are also estimated to boost pulmonary arterial hypertension market development through 2033.
The development of pulmonary arterial hypertension in people affected by HIV is a common probability and is slated to bolster demand for PAH diagnosis in the long run. New pulmonary arterial hypertension drug approvals and increasing awareness regarding the benefits of novel PAH therapies are projected to open up new avenues of opportunities for pulmonary arterial hypertension drug development companies going forward.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Which Drug Class is Likely to Accrue Maximum Gains?
“Therapeutic Advantages of Endothelin Receptor Antagonists Driving Their Popularity”
Endothelin receptor antagonists (ERAs) account for 45% share of the global PAH market at present.
Endothelin receptor antagonist drugs are widely suggested as a targeted therapy for reversing heart and lung damage, slowing PAH progression, and dilation of blood vessels, among other things. Clinical studies have shown that people with pulmonary arterial hypertension produce a lot of endothelin, which causes high blood pressure.
Physicians frequently prescribe endothelin receptor antagonists to lessen the amount of endothelin in the blood vessels. Furthermore, increasing investments in research and development efforts to offer new ERAs are expected to boost the PAH market growth.
Competitive Landscape
Top-tier pulmonary arterial hypertension treatment providers are focusing on hastening the launch of new products by investing more in R&D, which is resulting in a higher number of PAH clinical trials being performed around the world.
- In January 2023, Liquidia Corporation, a pharmaceutical company based in the United States, announced that it had raised US$ 100 million by entering into a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx). The company had plans of utilizing this capital to advance the R&D and manufacturing efforts for its pulmonary arterial hypertension treatment offerings.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Pulmonary Arterial Hypertension Industry Research
-
By Drug Class :
- Prostacyclin & Prostacyclin Analogs
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
-
By Pipeline Analysis :
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product modifications /Innovation 4. Key Success Factors 4.1. Strategic Developments 4.2. Key regulations 4.3. Product USPs /Technology 4.4. List of manufacturers and providers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP outlook 5.1.2. Increasing R&D Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. New product launches 5.2.2. Cost of products 5.2.3. Increasing adoption of Pulmonary Arterial Hypertension (PAH)s 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1. Current COVID19 Statistics and Probable Future Impact 6.2. Current GDP Projection and Probable Impact 6.3. Current Economic Projection as compared to 2008 Economic analysis 6.4. COVID19 and Impact Analysis 6.4.1. Revenue By Drug Class 6.4.2. Revenue By Pipeline Analysis 6.4.3. Revenue By Country 6.5. 2020 Market Scenario 6.6. Quarter by Quarter Forecast 6.7. Projected Recovery Quarter 7. Global Market Volume (Units) Analysis 2018-2022 and Forecast, 2023-2033 7.1. Historical Market Volume (Units) Analysis, 2018-2022 7.2. Current and Future Market Volume (Units) Projections, 2023-2033 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Market - Pricing Analysis 8.1. Regional Pricing Analysis By Drug Class 8.2. Pricing Break-up 8.2.1. Manufacturer Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 9. Global Market Value Analysis 2018-2022 and Forecast, 2023-2033 9.1. Historical Market Value (US$ Mn) Analysis, 2018-2022 9.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Drug Class 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Products & Services, 2018-2022 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2023-2033 10.3.1. Prostacyclin & Prostacyclin Analogs 10.3.2. Endothelin Receptor Antagonists (ERAs) 10.3.3. Phosphodiesterase-5 (PDE-5) Inhibitors 10.3.4. Soluble Guanylate Cyclase (sGC) Stimulators 10.4. Market Attractiveness Analysis By Drug Class 11. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Pipeline Analysis 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Pipeline Analysis, 2018-2022 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Pipeline Analysis, 2023-2033 11.3.1. Early-stage Drug Candidates (Phase I & Phase II) 11.3.2. Late-stage Drug Candidates (Phase III & Registration Phase) 11.4. Market Attractiveness Analysis By Pipeline Analysis 12. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2022 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2018-2022 and Forecast 2023-2033 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Drug Class 13.3.3. By Pipeline Analysis 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America Market Analysis 2018-2022 and Forecast 2023-2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Drug Class 14.3.3. By Pipeline Analysis 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018-2022 and Forecast 2023-2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. Rest of Europe 15.3.2. By Drug Class 15.3.3. By Pipeline Analysis 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Market Analysis 2018-2022 and Forecast 2023-2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Drug Class 16.3.3. By Pipeline Analysis 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia Market Analysis 2018-2022 and Forecast 2023-2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.1.4. Rest of East Asia 17.3.2. By Drug Class 17.3.3. By Pipeline Analysis 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania Market Analysis 2018-2022 and Forecast 2023-2033 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug Class 18.3.3. By Pipeline Analysis 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. Rest of Middle East and Africa 19.3.2. By Drug Class 19.3.3. By Pipeline Analysis 19.4. Market Attractiveness Analysis 19.5. Drivers and Restraints - Impact Analysis 20. Key and Emerging Countries Market Analysis 2018-2022 and Forecast 2023-2033 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Market Analysis 20.2.1. By Drug Class 20.2.2. By Pipeline Analysis 20.3. Canada Market Analysis 20.3.1. By Drug Class 20.3.2. By Pipeline Analysis 20.4. Mexico Market Analysis 20.4.1. By Drug Class 20.4.2. By Pipeline Analysis 20.5. Brazil Market Analysis 20.5.1. By Drug Class 20.5.2. By Pipeline Analysis 20.6. U.K. Market Analysis 20.6.1. By Drug Class 20.6.2. By Pipeline Analysis 20.7. Germany Market Analysis 20.7.1. By Drug Class 20.7.2. By Pipeline Analysis 20.8. France Market Analysis 20.8.1. By Drug Class 20.8.2. By Pipeline Analysis 20.9. Italy Market Analysis 20.9.1. By Drug Class 20.9.2. By Pipeline Analysis 20.10. Spain Market Analysis 20.10.1. By Drug Class 20.10.2. By Pipeline Analysis 20.11. BENELUX Market Analysis 20.11.1. By Drug Class 20.11.2. By Pipeline Analysis 20.12. Russia Market Analysis 20.12.1. By Drug Class 20.12.2. By Pipeline Analysis 20.13. China Market Analysis 20.13.1. By Drug Class 20.13.2. By Pipeline Analysis 20.14. Japan Market Analysis 20.14.1. By Drug Class 20.14.2. By Pipeline Analysis 20.15. South Korea Market Analysis 20.15.1. By Drug Class 20.15.2. By Pipeline Analysis 20.16. India Market Analysis 20.16.1. By Drug Class 20.16.2. By Pipeline Analysis 20.17. ASEAN Market Analysis 20.17.1. By Drug Class 20.17.2. By Pipeline Analysis 20.18. Australia Market Analysis 20.18.1. By Drug Class 20.18.2. By Pipeline Analysis 20.19. New Zealand Market Analysis 20.19.1. By Drug Class 20.19.2. By Pipeline Analysis 20.20. GCC Countries Market Analysis 20.20.1. By Drug Class 20.20.2. By Pipeline Analysis 20.21. Turkey Market Analysis 20.21.1. By Drug Class 20.21.2. By Pipeline Analysis 20.22. South Africa Market Analysis 20.22.1. By Drug Class 20.22.2. By Pipeline Analysis 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 21.4. Market Presence Analysis 21.4.1. By Regional footprint of Players 21.4.2. Product foot print by Players 21.4.3. Channel Foot Print by Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep dive 22.3.1. Gilead Sciences Inc. 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Profitability by Market Segments (Product/Channel/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Strategy Overview 22.3.1.5.1. Marketing Strategy 22.3.1.5.2. Product Strategy 22.3.1.5.3. Channel Strategy 22.3.2. Pfizer, Inc. 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Profitability by Market Segments (Product/Channel/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Strategy Overview 22.3.2.5.1. Marketing Strategy 22.3.2.5.2. Product Strategy 22.3.2.5.3. Channel Strategy 22.3.3. GlaxoSmithKline plc 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Profitability by Market Segments (Product/Channel/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Strategy Overview 22.3.3.5.1. Marketing Strategy 22.3.3.5.2. Product Strategy 22.3.3.5.3. Channel Strategy 22.3.4. Novartis International AG 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Profitability by Market Segments (Product/Channel/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Strategy Overview 22.3.4.5.1. Marketing Strategy 22.3.4.5.2. Product Strategy 22.3.4.5.3. Channel Strategy 22.3.5. Bayer HealthCare 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Profitability by Market Segments (Product/Channel/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Strategy Overview 22.3.5.5.1. Marketing Strategy 22.3.5.5.2. Product Strategy 22.3.5.5.3. Channel Strategy 22.3.6. United Therapeutics Corp 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Profitability by Market Segments (Product/Channel/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Strategy Overview 22.3.6.5.1. Marketing Strategy 22.3.6.5.2. Product Strategy 22.3.6.5.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
Table 08: Latin America Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
Table 11: Europe Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
Table 14: South Asia Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
Table 17: East Asia Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
Table 20: Oceania Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Drug Class
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018-2033, By Pipeline Analysis
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2018-2022
Figure 02: Global Market Volume Forecast (in 000' Units), 2023-2033
Figure 03: Pricing Analysis (US$) Per Product, By Region, 2022
Figure 04: Pricing Analysis (US$) Per Product, By Region, 2022
Figure 05: Global Market Value Analysis (US$ Mn), 2018-2022
Figure 06: Global Market Value Forecast (US$ Mn), 2023-2033
Figure 07: Global Market Absolute $ Opportunity, 2023-2033
Figure 08: Global Market Share Analysis (%), By Drug Class, 2023-2033
Figure 09: Global Market Y-o-Y Analysis (%), By Drug Class, 2023-2033
Figure 10: Global Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 11: Global Market Share Analysis (%), By Pipeline Analysis, 2023-2033
Figure 12: Global Market Y-o-Y Analysis (%), By Pipeline Analysis, 2023-2033
Figure 13: Global Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 14: Global Market Share Analysis (%), By Region, 2023-2033
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2023-2033
Figure 16: Global Market Attractiveness Analysis by Region, 2023-2033
Figure 17: North America Market Value Share, By Drug Class, 2023 (E)
Figure 18: North America Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 19: North America Market Value Share, By Country, 2023 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2018-2022
Figure 21: North America Market Value Forecast (US$ Mn), 2023-2033
Figure 22: North America Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 23: North America Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 24: North America Market Attractiveness Analysis by Country, 2023-2033
Figure 25: Latin America Market Value Share, By Drug Class, 2023 (E)
Figure 26: Latin America Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 27: Latin America Market Value Share, By Country, 2023 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2018-2022
Figure 29: Latin America Market Value Forecast (US$ Mn), 2023-2033
Figure 30: Latin America Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 31: Latin America Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 32: Latin America Market Attractiveness Analysis by Country, 2023-2033
Figure 33: Europe Market Value Share, By Drug Class, 2023 (E)
Figure 34: Europe Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 35: Europe Market Value Share, By Country, 2023 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2018-2022
Figure 37: Europe Market Value Forecast (US$ Mn), 2023-2033
Figure 38: Europe Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 39: Europe Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 40: Europe Market Attractiveness Analysis by Country, 2023-2033
Figure 41: South Asia Market Value Share, By Drug Class, 2023 (E)
Figure 42: South Asia Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 43: South Asia Market Value Share, By Country, 2023 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2018-2022
Figure 45: South Asia Market Value Forecast (US$ Mn), 2023-2033
Figure 46: South Asia Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 47: South Asia Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 48: South Asia Market Attractiveness Analysis by Country, 2023-2033
Figure 49: East Asia Market Value Share, By Drug Class, 2023 (E)
Figure 50: East Asia Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 51: East Asia Market Value Share, By Country, 2023 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2018-2022
Figure 53: East Asia Market Value Forecast (US$ Mn), 2023-2033
Figure 54: East Asia Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 55: East Asia Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 56: East Asia Market Attractiveness Analysis by Country, 2023-2033
Figure 57: Oceania Market Value Share, By Drug Class, 2023 (E)
Figure 58: Oceania Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 59: Oceania Market Value Share, By Country, 2023 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2018-2022
Figure 61: Oceania Market Value Forecast (US$ Mn), 2023-2033
Figure 62: Oceania Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 63: Oceania Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 64: Oceania Market Attractiveness Analysis by Country, 2023-2033
Figure 65: Middle East and Africa Market Value Share, By Drug Class, 2023 (E)
Figure 66: Middle East and Africa Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2023 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2018-2022
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2023-2033
Figure 70: Middle East and Africa Market Attractiveness Analysis by Drug Class, 2023-2033
Figure 71: Middle East and Africa Market Attractiveness Analysis by Pipeline Analysis, 2023-2033
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2023-2033
Figure 73: U. S. Market Value Analysis (US$ Mn), 2023 & 2033
Figure 74: U. S. Market Value Share, By Drug Class, 2023 (E)
Figure 75: U. S. Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2023 & 2033
Figure 77: Canada Market Value Share, By Drug Class, 2023 (E)
Figure 78: Canada Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2023 & 2033
Figure 80: Mexico Market Value Share, By Drug Class, 2023 (E)
Figure 81: Mexico Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2023 & 2033
Figure 83: Brazil Market Value Share, By Drug Class, 2023 (E)
Figure 84: Brazil Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2023 & 2033
Figure 86: U. K. Market Value Share, By Drug Class, 2023 (E)
Figure 87: U. K. Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2023 & 2033
Figure 89: Germany Market Value Share, By Drug Class, 2023 (E)
Figure 90: Germany Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2023 & 2033
Figure 92: France Market Value Share, By Drug Class, 2023 (E)
Figure 93: France Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2023 & 2033
Figure 95: Italy Market Value Share, By Drug Class, 2023 (E)
Figure 96: Italy Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2023 & 2033
Figure 98: Spain Market Value Share, By Drug Class, 2023 (E)
Figure 99: Spain Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2023 & 2033
Figure 101: Russia Market Value Share, By Drug Class, 2023 (E)
Figure 102: Russia Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2023 & 2033
Figure 104: China Market Value Share, By Drug Class, 2023 (E)
Figure 105: China Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2023 & 2033
Figure 107: Japan Market Value Share, By Drug Class, 2023 (E)
Figure 108: Japan Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2023 & 2033
Figure 110: South Korea Market Value Share, By Drug Class, 2023 (E)
Figure 111: South Korea Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2023 & 2033
Figure 113: India Market Value Share, By Drug Class, 2023 (E)
Figure 114: India Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2023 & 2033
Figure 116: ASEAN Market Value Share, By Drug Class, 2023 (E)
Figure 117: ASEAN Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2023 & 2033
Figure 119: Australia Market Value Share, By Drug Class, 2023 (E)
Figure 120: Australia Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2023 & 2033
Figure 122: New Zealand Market Value Share, By Drug Class, 2023 (E)
Figure 123: New Zealand Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2023 & 2033
Figure 125: GCC Countries Market Value Share, By Drug Class, 2023 (E)
Figure 126: GCC Countries Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2023 & 2033
Figure 128: Turkey Market Value Share, By Drug Class, 2023 (E)
Figure 129: Turkey Market Value Share, By Pipeline Analysis, 2023 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2023 & 2033
Figure 131: South Africa Market Value Share, By Drug Class, 2023 (E)
Figure 132: South Africa Market Value Share, By Pipeline Analysis, 2023 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the pulmonary arterial hypertension market in 2023?
The global pulmonary arterial hypertension market is valued at US$ 5.4 billion in 2023.
What is the projected market size for 2033?
The market for pulmonary arterial hypertension is predicted to reach US$ 12.7 billion by 2033.
At what CAGR will the PAH market expand over the next ten years?
From 2023 to 2033, the pulmonary arterial hypertension market is forecasted to rise at 5.4% CAGR.
Which class of drug is extensively used for PAH treatment?
Endothelin receptor antagonists (ERAs) currently account for 45% of the global PAH market share.
Who are the leading PAH drug manufacturing companies?
Pfizer Inc., GlaxoSmithKline Plc, Novartis International AG, Bayer HealthCare, and United Therapeutics Corp. are leading market players.
Pulmonary Arterial Hypertension (PAH) Market